10-Q Filing

MERCK & CO., INC. CIK: 310158 Q2 2021

Filing Information

Form Type	10-Q
Accession Number	`0000310158-21-000028`
Period End Date	20210630
Filing Date	20210809
Fiscal Year	2021
Fiscal Period	Q2
XBRL Instance	mrk-20210630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 86 Income Statement 80 Cash Flow Statement 78 Comprehensive Income 28

Balance Sheet 86 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$67.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$72.00M	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$2.07B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$2.41B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.16B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.05B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.57B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.24B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $72 in 2021 and $67 in 2020)	`AccountsReceivableNetCurrent`	$7.84B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $72 in 2021 and $67 in 2020)	`AccountsReceivableNetCurrent`	$6.80B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, shares authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, shares authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Inventories (excludes inventories of $2,412 in 2021 and $2,070 in 2020 classified in Other assets - see Note 7)	`InventoryNet`	$5.50B	USD	Point-in-time
Inventories (excludes inventories of $2,412 in 2021 and $2,070 in 2020 classified in Other assets - see Note 7)	`InventoryNet`	$5.55B	USD	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$6.75B	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$4.67B	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Treasury Stock, Shares	`TreasuryStockShares`	1.04B	shares	Point-in-time
Current assets of discontinued operations	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	-	USD	Point-in-time
Current assets of discontinued operations	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$2.68B	USD	Point-in-time
Treasury Stock, Shares	`TreasuryStockShares`	1.05B	shares	Point-in-time
Total current assets	`AssetsCurrent`	$27.76B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$28.66B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$411.00M	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$785.00M	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,236 in 2021 and $18,162 in 2020	`PropertyPlantAndEquipmentNet`	$17.00B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,236 in 2021 and $18,162 in 2020	`PropertyPlantAndEquipmentNet`	$18.06B	USD	Point-in-time
Goodwill	`Goodwill`	$18.87B	USD	Point-in-time
Goodwill	`Goodwill`	$18.88B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$13.62B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$14.10B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$9.88B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$11.05B	USD	Point-in-time
Noncurrent Assets of Discontinued Operations	`DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent`	-	USD	Point-in-time
Noncurrent Assets of Discontinued Operations	`DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent`	$3.17B	USD	Point-in-time
Total Assets	`Assets`	$90.69B	USD	Point-in-time
Total Assets	`Assets`	$91.59B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$6.43B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$2.49B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$4.33B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.90B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$12.89B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$12.21B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.60B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$971.00M	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.66B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.67B	USD	Point-in-time
Current liabilities of discontinued operations	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	-	USD	Point-in-time
Current liabilities of discontinued operations	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$1.09B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$27.33B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$21.91B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$24.03B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$25.36B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.49B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.00B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$9.87B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$12.31B	USD	Point-in-time
Noncurrent Liabilities of Discontinued Operations	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent`	-	USD	Point-in-time
Noncurrent Liabilities of Discontinued Operations	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent`	$186.00M	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2021 and 2020	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2021 and 2020	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.04B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$39.59B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$48.78B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$47.36B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-6.63B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.63B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$82.10B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$89.98B	USD	Point-in-time
Less treasury stock, at cost: 1,044,351,147 shares in 2021 and 1,046,877,695 shares in 2020	`TreasuryStockValue`	$56.79B	USD	Point-in-time
Less treasury stock, at cost: 1,044,351,147 shares in 2021 and 1,046,877,695 shares in 2020	`TreasuryStockValue`	$56.68B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$25.32B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$33.29B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$94.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$87.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$33.39B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.40B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$27.04B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.00B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.30B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$27.74B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$90.69B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$91.59B	USD	Point-in-time

Income Statement 80 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$9.35B	USD	1 Quarter
Sales	`Revenues`	$22.03B	USD	2 Qtrs
Sales	`Revenues`	$19.64B	USD	2 Qtrs
Sales	`Revenues`	$11.40B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.75B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$5.58B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$3.10B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$6.30B	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.08B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$4.47B	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.28B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$4.28B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$4.32B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$6.73B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.08B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$4.26B	USD	2 Qtrs
Restructuring costs	`RestructuringCharges`	$380.00M	USD	2 Qtrs
Restructuring costs	`RestructuringCharges`	$82.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$82.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$152.00M	USD	2 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$325.00M	USD	2 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$558.00M	USD	2 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$387.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$103.00M	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$17.32B	USD	2 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$9.69B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$6.61B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$13.94B	USD	2 Qtrs
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$4.70B	USD	2 Qtrs
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$2.74B	USD	1 Quarter
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$5.70B	USD	2 Qtrs
Income from Continuing Operations Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$1.72B	USD	1 Quarter
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$396.00M	USD	1 Quarter
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$503.00M	USD	1 Quarter
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$891.00M	USD	2 Qtrs
Taxes on Income from Continuing Operations	`IncomeTaxExpenseBenefit`	$741.00M	USD	2 Qtrs
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$2.35B	USD	1 Quarter
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$1.21B	USD	1 Quarter
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$3.96B	USD	2 Qtrs
Net Income from Continuing Operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$4.81B	USD	2 Qtrs
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$5.00M	USD	2 Qtrs
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$1.00M	USD	1 Quarter
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$4.00M	USD	1 Quarter
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity`	$-1.00M	USD	2 Qtrs
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$2.34B	USD	1 Quarter
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$3.96B	USD	2 Qtrs
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$1.21B	USD	1 Quarter
Net Income from Continuing Operations Attributable to Merck & Co., Inc.	`IncomeLossFromContinuingOperations`	$4.81B	USD	2 Qtrs
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$332.00M	USD	1 Quarter
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$1.41B	USD	2 Qtrs
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$766.00M	USD	2 Qtrs
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests	`IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity`	$661.00M	USD	1 Quarter
Net Income Attributable to Merck & Co. Inc.	`NetIncomeLoss`	$1.54B	USD	1 Quarter
Net Income Attributable to Merck & Co. Inc.	`NetIncomeLoss`	$6.22B	USD	2 Qtrs
Net Income Attributable to Merck & Co. Inc.	`NetIncomeLoss`	$3.00B	USD	1 Quarter
Net Income Attributable to Merck & Co. Inc.	`NetIncomeLoss`	$4.72B	USD	2 Qtrs
Income from Continuing Operations	`IncomeLossFromContinuingOperationsPerBasicShare`	$1.56	USD	2 Qtrs
Income from Continuing Operations	`IncomeLossFromContinuingOperationsPerBasicShare`	$0.93	USD	1 Quarter
Income from Continuing Operations	`IncomeLossFromContinuingOperationsPerBasicShare`	$0.48	USD	1 Quarter
Income from Continuing Operations	`IncomeLossFromContinuingOperationsPerBasicShare`	$1.90	USD	2 Qtrs
Income from Discontinued Operations	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	$0.56	USD	2 Qtrs
Income from Discontinued Operations	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	$0.26	USD	1 Quarter
Income from Discontinued Operations	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	$0.13	USD	1 Quarter
Income from Discontinued Operations	`DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare`	$0.30	USD	2 Qtrs
Net Income	`EarningsPerShareBasic`	$1.19	USD	1 Quarter
Net Income	`EarningsPerShareBasic`	$1.87	USD	2 Qtrs
Net Income	`EarningsPerShareBasic`	$0.61	USD	1 Quarter
Net Income	`EarningsPerShareBasic`	$2.46	USD	2 Qtrs
Income from Continuing Operations	`IncomeLossFromContinuingOperationsPerDilutedShare`	$0.92	USD	1 Quarter
Income from Continuing Operations	`IncomeLossFromContinuingOperationsPerDilutedShare`	$0.48	USD	1 Quarter
Income from Continuing Operations	`IncomeLossFromContinuingOperationsPerDilutedShare`	$1.89	USD	2 Qtrs
Income from Continuing Operations	`IncomeLossFromContinuingOperationsPerDilutedShare`	$1.56	USD	2 Qtrs
Income from Discontinued Operations	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	$0.55	USD	2 Qtrs
Income from Discontinued Operations	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	$0.26	USD	1 Quarter
Income from Discontinued Operations	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	$0.30	USD	2 Qtrs
Income from Discontinued Operations	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare`	$0.13	USD	1 Quarter
Net Income	`EarningsPerShareDiluted`	$1.18	USD	1 Quarter
Net Income	`EarningsPerShareDiluted`	$2.45	USD	2 Qtrs
Net Income	`EarningsPerShareDiluted`	$0.61	USD	1 Quarter
Net Income	`EarningsPerShareDiluted`	$1.86	USD	2 Qtrs

Cash Flow Statement 78 line items

Line Item	Tag	Value	Unit	Period
Restricted cash	`RestrictedCashAndCashEquivalents`	$55.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$103.00M	USD	Point-in-time
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$2.35B	USD	1 Quarter
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$1.21B	USD	1 Quarter
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$3.96B	USD	2 Qtrs
Net income from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$4.81B	USD	2 Qtrs
Amortization	`AdjustmentForAmortization`	$988.00M	USD	2 Qtrs
Amortization	`AdjustmentForAmortization`	$871.00M	USD	2 Qtrs
Depreciation	`Depreciation`	$808.00M	USD	2 Qtrs
Depreciation	`Depreciation`	$749.00M	USD	2 Qtrs
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	-	USD	2 Qtrs
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$20.00M	USD	2 Qtrs
Charge for the acquisition of Pandion Therapeutics, Inc.	`ResearchAndDevelopmentInProcess`	-	USD	2 Qtrs
Charge for the acquisition of Pandion Therapeutics, Inc.	`ResearchAndDevelopmentInProcess`	$1.56B	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$29.00M	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$101.00M	USD	2 Qtrs
Share-based compensation	`ShareBasedCompensation`	$213.00M	USD	2 Qtrs
Share-based compensation	`ShareBasedCompensation`	$243.00M	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$526.00M	USD	2 Qtrs
Other	`OtherNoncashIncomeExpense`	$204.00M	USD	2 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$3.65B	USD	2 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$4.11B	USD	2 Qtrs
Net Cash Provided by Operating Activities from Continuing Operations	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$2.62B	USD	2 Qtrs
Net Cash Provided by Operating Activities from Continuing Operations	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$3.23B	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$2.07B	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$1.55B	USD	2 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$1.00M	USD	2 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$77.00M	USD	2 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$1.89B	USD	2 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$386.00M	USD	2 Qtrs
Acquisition of Pandion Therapeutics, Inc. net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$1.55B	USD	2 Qtrs
Acquisition of Pandion Therapeutics, Inc. net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	2 Qtrs
Acquisition of ArQule, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	-	USD	2 Qtrs
Acquisition of ArQule, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	$2.54B	USD	2 Qtrs
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$90.00M	USD	2 Qtrs
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$321.00M	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-194.00M	USD	2 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-16.00M	USD	2 Qtrs
Net Cash Used in Investing Activities from Continuing Operations	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-3.31B	USD	2 Qtrs
Net Cash Used in Investing Activities from Continuing Operations	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-2.41B	USD	2 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$1.97B	USD	2 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$-3.98B	USD	2 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$1.95B	USD	2 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$1.15B	USD	2 Qtrs
Distribution from Organon & Co.	`DisposalGroupIncludingDiscontinuedOperationsDistributionReceived`	-	USD	2 Qtrs
Distribution from Organon & Co.	`DisposalGroupIncludingDiscontinuedOperationsDistributionReceived`	$9.00B	USD	2 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$4.45B	USD	2 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	2 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$1.28B	USD	2 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$239.00M	USD	2 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$3.32B	USD	2 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$3.13B	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$40.00M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$51.00M	USD	2 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-444.00M	USD	2 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-194.00M	USD	2 Qtrs
Net Cash Provided by (Used in) Financing Activities from Continuing Operations	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-353.00M	USD	2 Qtrs
Net Cash Provided by (Used in) Financing Activities from Continuing Operations	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$164.00M	USD	2 Qtrs
Net cash provided by operating activities	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	$1.45B	USD	2 Qtrs
Net cash provided by operating activities	`CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations`	$1.05B	USD	2 Qtrs
Net cash used in investing activities	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	$-100.00M	USD	2 Qtrs
Net cash used in investing activities	`CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations`	$-134.00M	USD	2 Qtrs
Net cash used in financing activities	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	$-504.00M	USD	2 Qtrs
Net cash used in financing activities	`CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations`	-	USD	2 Qtrs
Net Cash Flows Provided by Discontinued Operations	`NetCashProvidedByUsedInDiscontinuedOperations`	$413.00M	USD	2 Qtrs
Net Cash Flows Provided by Discontinued Operations	`NetCashProvidedByUsedInDiscontinuedOperations`	$1.35B	USD	2 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.00M	USD	2 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-19.00M	USD	2 Qtrs
Net Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$477.00M	USD	2 Qtrs
Net Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.21B	USD	2 Qtrs
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $103 at January 1, 2021 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.93B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $103 at January 1, 2021 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.15B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $103 at January 1, 2021 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.63B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $103 at January 1, 2021 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.15B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $55 at June 30, 2021 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.93B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $55 at June 30, 2021 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.15B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $55 at June 30, 2021 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.63B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $55 at June 30, 2021 included in Other Assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$11.15B	USD	Point-in-time

Comprehensive Income 28 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.54B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$6.22B	USD	2 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.00B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.72B	USD	2 Qtrs
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$240.00M	USD	2 Qtrs
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$10.00M	USD	1 Quarter
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-120.00M	USD	1 Quarter
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-16.00M	USD	2 Qtrs
Net unrealized loss on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	-	USD	1 Quarter
Net unrealized loss on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-18.00M	USD	2 Qtrs
Net unrealized loss on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	-	USD	1 Quarter
Net unrealized loss on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	-	USD	2 Qtrs
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-1.48B	USD	2 Qtrs
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-39.00M	USD	1 Quarter
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-99.00M	USD	2 Qtrs
Benefit plan net gain and prior service credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-1.40B	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-265.00M	USD	2 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$132.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$79.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-167.00M	USD	2 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$1.54B	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-200.00M	USD	2 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-2.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$1.56B	USD	2 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$6.02B	USD	2 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$3.09B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$3.00B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$6.28B	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.